|
Fleischmann Jr, W R; Koren, S (1999) Systemic effects of orally administered interferons and interleukin-2. J Interferon Cytokine Res 19:829-39
|
|
Wu, T Y; Fleischmann Jr, W R (1998) Efficacy of B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16alpha cells) as a tumor vaccine in mice. J Interferon Cytokine Res 18:829-39
|
|
Fleischmann, C M; Wu, T Y; Fleischmann Jr, W R (1997) B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16 alpha cells) as activators of tumor immunity in mice. J Interferon Cytokine Res 17:37-43
|
|
Fleischmann, C M; Stanton, G J; Fleischmann Jr, W R (1996) Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J Interferon Cytokine Res 16:805-12
|
|
Fleischmann, C M; Fleischmann Jr, W R (1995) Enhanced in vitro macrophage cytotoxicity against interferon-treated B16 melanoma cells. J Biol Regul Homeost Agents 9:139-45
|
|
Koren, S; Fleischmann Jr, W R (1994) Modulation of peripheral leukocyte counts and bone marrow function in mice by oral administration of interleukin-2. J Interferon Res 14:343-7
|
|
Fleischmann Jr, W R; Fleischmann, C M (1994) Enhancement of MuIFN-gamma antitumor effects by hyperthermia: sequence dependence and time dependence of hyperthermia. J Biol Regul Homeost Agents 8:101-7
|
|
Fleischmann, C M; Stanton, G J; Fleischmann Jr, W R (1994) Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice. Cancer Immunol Immunother 39:148-54
|
|
Koren, S; Fleischmann Jr, W R (1993) Optimal circadian timing reduces the myelosuppressive activity of recombinant murine interferon-gamma administered to mice. J Interferon Res 13:187-95
|
|
Koren, S; Fleischmann Jr, W R (1993) Circadian variations in myelosuppressive activity of interferon-alpha in mice: identification of an optimal treatment time associated with reduced myelosuppressive activity. Exp Hematol 21:552-9
|
Showing the most recent 10 out of 17 publications
